Gain Therapeutics (GANX) News Today $1.94 +0.05 (+2.70%) Closing price 03:58 PM EasternExtended Trading$2.00 +0.06 (+3.25%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Gain Therapeutics to Participate at The Citizens Life Sciences ConferenceMay 1, 2025 | globenewswire.comGain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Recommendation of "Buy" from BrokeragesMay 1, 2025 | americanbankingnews.comGain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related DisordersApril 30, 2025 | finance.yahoo.comGain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related DisordersApril 30, 2025 | globenewswire.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Buy" by BrokeragesShares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have been given an average rating of "Buy" by the six analysts that are covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommenApril 28, 2025 | marketbeat.comGain Therapeutics (NASDAQ:GANX) Trading Up 1.6% - Here's WhyGain Therapeutics (NASDAQ:GANX) Trading Up 1.6% - Still a Buy?April 27, 2025 | marketbeat.comGain Therapeutics presents additional data on study of GT-02287April 11, 2025 | markets.businessinsider.comIs Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?April 11, 2025 | insidermonkey.comQ1 Earnings Forecast for GANX Issued By Roth CapitalGain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - Equities researchers at Roth Capital issued their Q1 2026 EPS estimates for shares of Gain Therapeutics in a research note issued to investors on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan forecasts that the company will earn ($0April 2, 2025 | marketbeat.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Buy" by AnalystsGain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six research firms that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buApril 2, 2025 | marketbeat.comGain Therapeutics (GANX) Receives a Buy from Roth MKMMarch 31, 2025 | markets.businessinsider.comGain Therapeutics (NASDAQ:GANX) Releases Earnings Results, Beats Estimates By $0.07 EPSGain Therapeutics (NASDAQ:GANX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07.March 29, 2025 | marketbeat.comChardan Capital Reaffirms "Buy" Rating for Gain Therapeutics (NASDAQ:GANX)Chardan Capital reissued a "buy" rating and set a $6.00 price target on shares of Gain Therapeutics in a report on Friday.March 29, 2025 | marketbeat.comGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate UpdateMarch 28, 2025 | finanznachrichten.deScotiabank Keeps Their Buy Rating on Gain Therapeutics (GANX)March 28, 2025 | markets.businessinsider.comGain Therapeutics Announces Poster Presentation at AD/PD 2025March 28, 2025 | globenewswire.comGain Therapeutics reports FY24 EPS (89c), consensus ($1.00)March 27, 2025 | markets.businessinsider.comGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate UpdateMarch 27, 2025 | globenewswire.comGain Therapeutics (NASDAQ:GANX) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of Gain Therapeutics in a research note on Monday.March 18, 2025 | marketbeat.comGain Therapeutics (GANX) to Release Quarterly Earnings on TuesdayGain Therapeutics (NASDAQ:GANX) will be releasing earnings before the market opens on Tuesday, March 25, Financial Modeling Prep reports.March 18, 2025 | marketbeat.comShort Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 24.5%Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 348,800 shares, a decline of 24.5% from the February 13th total of 462,200 shares. Approximately 1.4% of the company's stock are sold short. Based on an average trading volume of 232,700 shares, the short-interest ratio is presently 1.5 days.March 17, 2025 | marketbeat.comGain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s DiseaseMarch 14, 2025 | markets.businessinsider.comGain Therapeutics doses first participant in Phase 1b trial of GT-02287March 14, 2025 | markets.businessinsider.comGain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's DiseaseMarch 14, 2025 | globenewswire.comScotiabank Initiates Coverage of Gain Therapeutics (GANX) with Sector Outperform RecommendationMarch 8, 2025 | msn.comGain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Buy" from AnalystsGain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has earned a consensus rating of "Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy reMarch 8, 2025 | marketbeat.comGain Therapeutics initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comGain Therapeutics Announces Oral Presentation at AD/PD 2025March 6, 2025 | globenewswire.comGain Therapeutics, Inc.: Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational UpdateFebruary 6, 2025 | finanznachrichten.deGain Therapeutics CEO says 2025 ‘poised to be another pivotal year’February 6, 2025 | markets.businessinsider.comGain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational UpdateFebruary 6, 2025 | globenewswire.comGain Therapeutics (NASDAQ:GANX) Shares Up 10.4% - What's Next?Gain Therapeutics (NASDAQ:GANX) Shares Up 10.4% - Still a Buy?February 6, 2025 | marketbeat.comGain Therapeutics To Participate in Upcoming Investor ConferencesFebruary 5, 2025 | globenewswire.comGain Therapeutics regains compliance with Nasdaq listingJanuary 16, 2025 | msn.comRoth MKM Sticks to Its Buy Rating for Gain Therapeutics (GANX)January 9, 2025 | markets.businessinsider.comGain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287January 9, 2025 | markets.businessinsider.comGain Therapeutics Appoints Gene Mack as Chief Executive Officer and DirectorJanuary 7, 2025 | markets.businessinsider.comGain Therapeutics Appoints Gene Mack As CEOJanuary 7, 2025 | markets.businessinsider.comGain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good ResultsDecember 31, 2024 | seekingalpha.comGain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKMDecember 25, 2024 | markets.businessinsider.comGain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s DiseaseDecember 23, 2024 | markets.businessinsider.comGain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's DiseaseDecember 23, 2024 | globenewswire.comGain Therapeutics To Present At Biotech Showcase 2025December 11, 2024 | globenewswire.comRoth MKM Initiates Coverage of Gain Therapeutics (GANX) with Buy RecommendationDecember 6, 2024 | msn.comPromising Preclinical Data and Financial Position Support Buy Rating for Gain TherapeuticsNovember 26, 2024 | markets.businessinsider.comOptimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 TrialsNovember 21, 2024 | markets.businessinsider.comGain Therapeutics Advances Parkinson’s Therapy DevelopmentNovember 20, 2024 | markets.businessinsider.comGain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson’s DiseaseNovember 19, 2024 | markets.businessinsider.comGain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate UpdateNovember 15, 2024 | markets.businessinsider.comShort Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 12.6%Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 572,000 shares, a decline of 12.6% from the September 30th total of 654,300 shares. Currently, 2.4% of the shares of the company are short sold. Based on an average daily volume of 387,000 shares, the short-interest ratio is currently 1.5 days.October 29, 2024 | marketbeat.com Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address GANX Media Mentions By Week GANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GANX News Sentiment▼0.210.64▲Average Medical News Sentiment GANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GANX Articles This Week▼31▲GANX Articles Average Week Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Canopy Growth News Bright Minds Biosciences News Genfit News Protalix BioTherapeutics News Ocugen News ProKidney News Amarin News Nuvectis Pharma News Foghorn Therapeutics News SOPHiA GENETICS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GANX) was last updated on 5/7/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GANX Stock Free GANX Stock Alerts